Does the media favor ADMA or LGND?

In the previous week, Ligand Pharmaceuticals had 18 more articles in the media than ADMA Biologics. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.27 beat Ligand Pharmaceuticals' score of 0.30 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to LGND or ANIP?

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 12 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.88 beat Ligand Pharmaceuticals' score of 0.30 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral ANI Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GMAB or LGND?

In the previous week, Ligand Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 6 mentions for Genmab A/S. Ligand Pharmaceuticals' average media sentiment score of 0.30 beat Genmab A/S's score of 0.29 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer LGND or UTHR?

In the previous week, United Therapeutics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for United Therapeutics and 21 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 0.91 beat Ligand Pharmaceuticals' score of 0.30 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral United Therapeutics 10 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LGND or ASND?

In the previous week, Ligand Pharmaceuticals had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.35 beat Ligand Pharmaceuticals' score of 0.30 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ascendis Pharma A/S 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Ligand Pharmaceuticals (LGND) Competitors

$301.52 +2.48 (+0.83%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$302.10 +0.58 (+0.19%)

As of 09/25/2026 07:30 PM Eastern

Compare

LGND vs. ADMA, ANIP, GMAB, UTHR, and ASND

Should you buy Ligand Pharmaceuticals stock or one of its competitors? Ligand Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Genmab A/S (GMAB), United Therapeutics (UTHR), and Ascendis Pharma A/S (ASND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

ADMA Biologics currently has a consensus price target of $18.67, indicating a potential upside of 99.00%. Ligand Pharmaceuticals has a consensus price target of $337.89, indicating a potential upside of 12.06%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has a net margin of 67.88% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

In the previous week, Ligand Pharmaceuticals had 18 more articles in the media than ADMA Biologics. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.27 beat Ligand Pharmaceuticals' score of 0.30 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.12	$146.93M	$0.70	13.40
Ligand Pharmaceuticals	$268.09M	22.43	$124.45M	$9.35	32.25

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ADMA Biologics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 67.88% compared to ANI Pharmaceuticals' net margin of 11.07%. ANI Pharmaceuticals' return on equity of 27.37% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Ligand Pharmaceuticals currently has a consensus price target of $337.89, indicating a potential upside of 12.06%. ANI Pharmaceuticals has a consensus price target of $98.00, indicating a potential upside of 32.43%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 12 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.88 beat Ligand Pharmaceuticals' score of 0.30 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.43	$124.45M	$9.35	32.25
ANI Pharmaceuticals	$883.37M	1.92	$78.34M	$4.64	15.95

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Genmab A/S presently has a consensus price target of $39.50, indicating a potential upside of 11.83%. Ligand Pharmaceuticals has a consensus price target of $337.89, indicating a potential upside of 12.06%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Genmab A/S has higher revenue and earnings than Ligand Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.13B	5.33	$963M	$1.27	27.81
Ligand Pharmaceuticals	$268.09M	22.43	$124.45M	$9.35	32.25

Ligand Pharmaceuticals has a net margin of 67.88% compared to Genmab A/S's net margin of 19.08%. Ligand Pharmaceuticals' return on equity of 20.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

In the previous week, Ligand Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 6 mentions for Genmab A/S. Ligand Pharmaceuticals' average media sentiment score of 0.30 beat Genmab A/S's score of 0.29 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats Genmab A/S on 14 of the 17 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

Ligand Pharmaceuticals (NASDAQ:LGND) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, United Therapeutics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for United Therapeutics and 21 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 0.91 beat Ligand Pharmaceuticals' score of 0.30 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
United Therapeutics	10 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to United Therapeutics' net margin of 41.56%. United Therapeutics' return on equity of 20.18% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
United Therapeutics	41.56%	20.18%	17.98%

Ligand Pharmaceuticals currently has a consensus price target of $337.89, indicating a potential upside of 12.06%. United Therapeutics has a consensus price target of $621.00, indicating a potential upside of 30.61%. Given United Therapeutics' higher possible upside, analysts plainly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.43	$124.45M	$9.35	32.25
United Therapeutics	$3.18B	6.41	$1.33B	$27.95	17.01

Summary

United Therapeutics beats Ligand Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Ligand Pharmaceuticals (NASDAQ:LGND) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Ligand Pharmaceuticals had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.35 beat Ligand Pharmaceuticals' score of 0.30 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 70.99% compared to Ligand Pharmaceuticals' net margin of 67.88%. Ascendis Pharma A/S's return on equity of 32.54% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Ligand Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.43	$124.45M	$9.35	32.25
Ascendis Pharma A/S	$814.57M	17.28	-$258M	$12.89	17.50

Ligand Pharmaceuticals currently has a consensus price target of $337.89, suggesting a potential upside of 12.06%. Ascendis Pharma A/S has a consensus price target of $310.75, suggesting a potential upside of 37.74%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Ligand Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.01B	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.04%
P/E Ratio	32.25	14.15	275.82	25.78
Price / Sales	22.43	1,405.67	638.64	85.46
Price / Cash	38.40	120.91	79.52	52.89
Price / Book	5.83	15.28	10.44	6.30
Net Income	$124.45M	-$22.90M	$3.51B	$360.35M
7 Day Performance	6.36%	-2.94%	-1.31%	-0.23%
1 Month Performance	5.97%	-8.80%	-4.61%	-4.16%
1 Year Performance	77.66%	28.99%	15.01%	4.58%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	3.3079 of 5 stars	$301.52 +0.8%	$337.89 +12.1%	+77.7%	$6.01B	$268.09M	32.25	47	Trending News Analyst Forecast
ADMA ADMA Biologics	3.2292 of 5 stars	$9.11 +1.8%	$18.67 +104.9%	-39.9%	$2.04B	$510.17M	13.01	647	Positive News High Trading Volume
ANIP ANI Pharmaceuticals	4.581 of 5 stars	$76.14 +1.0%	$103.00 +35.3%	-20.5%	$1.75B	$978.38M	16.41	970	Analyst Forecast High Trading Volume
GMAB Genmab A/S	4.1251 of 5 stars	$34.74 +0.6%	$39.50 +13.7%	+21.5%	$21.67B	$4.13B	27.35	3,029	News Coverage
UTHR United Therapeutics	4.5088 of 5 stars	$494.63 -0.5%	$646.00 +30.6%	+9.9%	$21.21B	$3.18B	17.70	1,400	Trending News Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, GMAB, UTHR, and ASND

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, GMAB, UTHR, and ASND

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Do analysts recommend ADMA or LGND?

Is ADMA or LGND more profitable?

Does the media favor ADMA or LGND?

Which has higher earnings & valuation, ADMA or LGND?

Do insiders and institutionals believe in ADMA or LGND?

Which has more risk & volatility, ADMA or LGND?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Do institutionals and insiders believe in LGND or ANIP?

Which has more volatility & risk, LGND or ANIP?

Is LGND or ANIP more profitable?

Do analysts prefer LGND or ANIP?

Does the media refer more to LGND or ANIP?

Which has preferable valuation & earnings, LGND or ANIP?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Do analysts prefer GMAB or LGND?

Which has more risk & volatility, GMAB or LGND?

Which has preferable earnings & valuation, GMAB or LGND?

Is GMAB or LGND more profitable?

Does the media favor GMAB or LGND?

Do institutionals & insiders have more ownership in GMAB or LGND?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Does the media prefer LGND or UTHR?

Is LGND or UTHR more profitable?

Do analysts rate LGND or UTHR?

Do institutionals & insiders believe in LGND or UTHR?

Which has more volatility and risk, LGND or UTHR?

Which has preferable earnings and valuation, LGND or UTHR?

Summary

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Does the media refer more to LGND or ASND?

Do institutionals and insiders hold more shares of LGND or ASND?

Is LGND or ASND more profitable?

Which has stronger valuation and earnings, LGND or ASND?

Do analysts recommend LGND or ASND?

Which has more volatility and risk, LGND or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools